Complexes for delivery of antigenic peptides

Patent metadata

Field	Value
Publication number	US-11701433-B2
Application number	US-201816619802-A
Country	US
Kind code	B2
Filing date	Jun 1, 2018
Priority date	Jun 5, 2017
Publication date	Jul 18, 2023
Grant date	Jul 18, 2023

Abstract

The present invention provides methods, compositions, systems, and kits comprising nano-satellite complexes and/or serum albumin carrier complexes, which are used for modulating antigen-specific immune response (e.g., enhancing anti-tumor immunity). In certain embodiments, the nano-satellite complexes comprise: a) a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; b) at least one satellite particle attached to, or absorbed to, the biocompatible coating; and c) an antigenic component conjugated to, or absorbed to, the at least one satellite particle component. In certain embodiments, the complexes further comprise: d) an type I interferon agonist agent. In some embodiments, the serum albumin complexes comprise: a) at least part of a serum albumin protein, b) an antigenic component conjugated to the carrier protein, and c) a type I interferon agonist agent.

First claim

We claim:

1. A method of treating head and neck squamous cell carcinoma (HNSCC) in a subject comprising: administering to a subject having at least one HNSCC tumor:
a) a composition comprising a nano-satellite complex, wherein said nano-satellite complex comprises:
i) a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core;
ii) at least one satellite particle attached to, or absorbed to, said biocompatible coating;
iii) an antigenic component conjugated to, or absorbed to, said at least one satellite particle component, wherein said antigenic component comprises an antigenic peptide, wherein said antigenic peptide comprises at least one epitope from a viral oncoprotein; and
iv) a type I interferon agonist agent which is electrostatically attracted to, or absorbed to, said antigenic component; and

b) an immune checkpoint inhibitor.

2. The method of claim 1 , wherein said nanoparticle core comprises Fe3O4, said biocompatible coating comprises polysiloxane, and said at least one satellite particle comprises a plurality of satellite particles composed of gold.

3. The method of claim 1 , wherein said type I interferon agonist agent is selected from the group consisting of: c-di-GMP, c-di-AMP, cGAMP, c-di-IMP, c-di-UMP, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), 2′3′-cGAM(PS)2 (Rp/Sp), 2′3′-c-di-AM(PS)2 (Rp,Rp), and a STING agonist.

4. The method of claim 1 , wherein said at least one tumor comprises a plurality of HNSCC cancer cells, and wherein said administering kills at least some of said plurality of HNSCC cancer cells.

5. The method of claim 1 , wherein said subject is a human.

6. The method of claim 1 , wherein said administering generates an immune response in said subject making them resistant to infection by infectious agents.

Assignees

• Univ Michigan Regents

Inventors

• Lei Yu
• Tan Yee Sun
• Sansanaphongpricha Kanokwan
• Sun Duxin
• Chen Hongwei
• Hu Hongxiang

Classifications

• A61K39/0011

  Cancer antigens · CPC title

• A61K47/6929 Primary

  the form being a nanoparticle, e.g. an immuno-nanoparticle · CPC title

• A61K39/0003

  Invertebrate antigens · CPC title

• A61K39/02

  Bacterial antigens · CPC title

• A61K39/118

  Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci · CPC title